Published online before print April 24, 2006, doi: 10.1161/01.HYP.0000221065.05670.23
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2006;47:1067.)
© 2006 American Heart Association, Inc.
Original Articles |
Angiotensinogen Modulates Renal Vasculature Growth
From the Institut National de la Santé et de la Recherche Médicale Unité 36 (M.B., N.L., E.L., P.C., J.-M.G.), Pathologie Vasculaire et Endocrinologie Rénale, Chaire de Médecine Expérimentale, Collège de France, Paris, France; Department of Internal Medicine (C.D.S.), University of Iowa, Department of Internal Medicine, Iowa City, IA.
Correspondence to Jean-Marie Gasc, INSERM U36, Collège de France, 11, place Marcelin Berthelot, 75231 Paris Cedex 05, France. E-mail jean-marie.gasc{at}college-de-france.fr
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
We have shown previously that angiotensinogen, like other members of the serine protease inhibitor family, has antiangiogenic properties in vitro on cultured endothelial cells and in ovo in the chick chorioallantoic membrane assay. The aim of this study was to show the effects of angiotensinogen on vascular wall remodeling in vivo. We measured the vessel wall thickness (tunica media) stained with an antibody to
-actin. In the kidney, arterioles were 21.5% thinner in male transgenic mice overexpressing human angiotensinogen than in male control animals. In other vascular beds, the arterial wall thickness was not affected. By using in situ hybridization and Northern blot analysis, human angiotensinogen expression was detected at a high level in the male kidney and at a much lower level in other organs. There is a relationship between the effect of angiotensinogen on arterial wall thickness and the local expression level of angiotensinogen in this model of transgenic mice. Because human angiotensinogen is not cleaved to a significant extent by mouse renin, the reduction in kidney arterial wall thickness is because of angiotensinogen itself and not angiotensin II, and we show that the reduction was not because of hypoplasia or hypotropia. In contrast, a marked difference in the expression of platelet-derived growth factor receptor-ß was observed in the kidney arterioles at day 5 when compared with controls. Altogether, these observations provide the first quantitative evidence that a high level of angiotensinogen expression can inhibit the growth of kidney artery walls in vivo.
Key Words: angiotensinogen • muscle, smooth, vascular • remodeling • vessels • animals, transgenic
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Angiotensinogen (AGT) is a 452-amino acid protein that is synthesized mainly in the liver.1 It is the only known precursor of angiotensin I (Ang I), an inactive decapeptide that is further converted by Ang I-converting enzyme into angiotensin II (Ang II), the main effector of the renin–angiotensin system.1 AGT belongs to the family of noninhibitory serpins, as revealed by its gene organization, amino acid sequence, and secondary structure.2 Several serpins (eg, maspin, pigment epithelium-derived factor, antithrombin III, and kallistatin) are known to have antiangiogenic effects.3–6 We showed recently that AGT also displays antiangiogenic properties in vitro and in ovo.7 AGT inhibits the proliferation of cultured endothelial cells, blocks the formation of capillaries on Matrigel, and impairs the formation of capillaries in the chick chorioallantoic membrane assay.7 In addition, an adenovirus encoding human AGT exhibits strong antiangiogenic and thereby antitumoral effects in different experimental tumor models in mice.8
Several indirect observations suggest the implication of AGT in vascular wall remodeling. As shown by Northern blot analysis and in situ hybridization studies, AGT is produced locally in vascular smooth muscle cells (VSMCs), that is, the tunica media of large blood vessels.9,10 Physiologically, AGT may also be involved in the stability of the blood brain barrier: Kakinuma et al11 demonstrated that AGT-deficient mice exposed to cold stress for several days exhibit a massive and irreversible edema of the brain because of impaired blood–brain barrier permeability, which could be corrected by Ang II or angiotensin IV administration. The same group showed that renin-deficient mice and wild-type (WT) mice did not exhibit this phenotype,12 suggesting that the observed vascular brain barrier abnormality in AGT-deficient mice was either because of a lack of local AGT, per se, or because of an alternative pathway for generating angiotensin peptides. The purpose of the present study was to determine whether human AGT is directly implicated in vascular wall remodeling. We measured the vessel wall thickness of a wide size range of kidney arterioles in 5-, 15-, and adult 60-day-old male and female transgenic mice overexpressing human AGT (Hu-AGT-TG mice).13 We used mice that overproduced human AGT to study the role of AGT, per se, because mouse renin does not cleave human AGT to a significant extent.
In 60-day-old male Hu-AGT-TG mice, the walls of kidney arterioles are thinner than those from male control animals. A reduction in arteriole wall thickness of kidney was already observed in 15-day-old male Hu-AGT-TG mice, whereas no reduction in vessel wall thickness of kidney arteries was observed in 5-day-old Hu-AGT-TG mice in comparison with their controls. A reduction in arterial wall thickness was not observed in other organs that do not express large amounts of the human AGT transgene (heart, white adipose tissue, and mesenteric artery system). This suggests a direct relationship between the level of AGT expression and arterial wall thickness. Human AGT, therefore, exerts a paracrine rather than an endocrine action on the arterial walls of male Hu-AGT-TG mice.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animal Models
All of the animal procedures for the care and use of laboratory animals were conducted according to the guidelines of our institution and Federation of European Laboratory Animal Science Association.
Hu-AGT-TG Mice
Hu-AGT-TG mice were generated as described previously.13 Briefly, the transgene consisted of all 5 exons of the human AGT gene and the intervening introns plus &1.2 kb upstream and 1.4 kb downstream of the human gene. This 14-kb genomic construct was injected into (C57BL/6JxSJL/J)F2 1-cell fertilized mouse embryos, thus generating transgenic mice. Germ line transmission was &50%, with an equal distribution between males and females. Hu-AGT-TG mice were maintained in a heterozygous state by consecutive 10 backcross breeding to C57BL/6 mice. The Ang II plasma concentration, blood pressure, and phenotype of Hu-AGT-TG mice have been reported and are indistinguishable from those of the control mice.13
Tissue Preparation
Organs were collected from 5-, 15-, and 60-day-old adult male and female mice (control and genetically engineered animals) and fixed in 4% paraformaldehyde in PBS. After dehydratation and embedding in paraplast, serial sagittal sections were cut (7 mm) and mounted on silanated slides.
Immunohistochemistry
Histological sections were immunostained with a mouse monoclonal antibody to -actin of VSMCs (dilution 1:500; M 0851; DAKO-Cytomation). To prevent nonspecific staining because of the use of antimouse IgG on mouse tissue sections, we used the kit ARK (DAKO-Cytomation) according to the supplier’s instructions. Apoptosis was detected with an antibody to activated caspase-3 (dilution 1:300; 9661; Cell Signaling) according to a standard immunostaining technique with secondary biotinylated antibody (dilution 1:200; BA 2000; Vector Laboratories) followed by the avidin–biotin–peroxidase complex amplification system (ABC Elite kit, Vector Laboratories) using diaminobenzidine as a chromogen.
Apoptosis
Apoptotic cells were stained using the TUNEL technique. Sections were treated with 5 mg/mL proteinase K (Roche) for 8 minutes at room temperature. The TUNEL reaction was performed at 37°C for 1 hour in a humidified chamber, using 0.5 nmol of biotin-labeled deoxyuridine triphosphate (Enzo) and 12.5 U of recombinant terminal deoxynucleotide transferase (Invitrogen).
Proliferation
Proliferation of VSMCs was assessed by immunostaining with antiproliferating cell nuclear antigen (dilution 1:1000; NCL-PCNA; Novocastra) and anti-Ki-67 (dilution 1:1000; M 7240; DAKO-Cytomation) antibodies using a standard immunostaining technique and the biotin–tyramin amplification.
In Situ Hybridization
The abdominal part of the body of control and Hu-AGT-TG mice at day 5 and day 15 was fixed in 4% paraformaldehyde and processed for histology and for in situ hybridization as described previously.14 Single-strand sense and antisense riboprobes, labeled with 35S-UTP (Amersham Biosciences), were generated by in vitro transcription from a 1659-bp human AGT cDNA, cloned in pECEI, from an 800-bp mouse platelet-derived growth factor (PDGF)-B cDNA and from a 816-bp mouse PDGF-Rß cDNA, both cloned in pBluescriptSK.
Vessel Wall Measurement
Histologic sections were immunostained with an antibody to smooth muscle -actin, a marker of the tunica media of arteries (Figure 1 A and 1B). The blood vessels examined were cut in a plane perpendicular to the axis of the vessels. Each vessel was scanned with a digital camera (Digital Microscope Camera, Polaroid), and the following parameters were directly measured on the computer monitor using the IPLab software (IPLab, Scanalytics, Figure 1C): (1) the surface (S) of the vessels, corresponding with the area between the inner and outer limits of the vessel wall, that is, the tunica media, as defined by -actin immunostaining; and (2) the length of the major axis (L), that is, the longest external dimension (diameter) of the vessel section (Figure 1C, arrow). The S/L ratio was calculated to normalize wall thickness to the vessel diameter. Under the assumption that the vessel section is a circle or an ellipse, this parameter is directly proportional to the vessel wall thickness. The average wall thickness for each mouse was the mean value obtained from measurements of 20 to 25 vessels per mouse. Only arteries with an L value between 10 and 150 µm were measured. All of the measurements were performed blindly.
|
Density of VSMC in the Vessel Wall
Kidney sections of 60-day-old male WT and male Hu-AGT-TG mice were stained with hematoxylin/eosin, and the stained VSMC nuclei were counted and expressed as a ratio to the surface of the vessel wall immunostained for -actin (see above).
Culture of VSMC
Human umbilical arterial smooth muscle cells (HUSMCs), human aortic smooth muscle cells (HAoSMCs), and rat aortic smooth muscle cells were obtained from Clonetics (Cambrex BioScience) and cultured in the medium provided by the supplier. For proliferation experiments, HUSMCs or HAoSMCs were seeded at a density of 10 000 cells/well in collagen-coated wells (24-well culture plates). After 24 hours, HUSMCs or HAoSMCs were starved in 0.2% fetal calf serum for 30 hours. Proliferation, as assessed by measuring the amount of 3H-thymidine (Amersham) incorporated in 24 hours, was stimulated by adding 2.5 ng/mL of human basic fibroblast growth factor (Cambrex BioScience). Then cells were treated with 10% trichloroacetic acid and solubilized (200 mmol/L NaOH). The radioactivity incorporated in the DNA was measured by liquid scintillation counting. AGT at concentrations between 1 and 5000 nmol/L was tested on cell proliferation.
Hormone Measurements
Blood was collected into chilled tubes containing EDTA. Plasma concentration of human AGT was measured indirectly, as described by Clauser et al,15 using recombinant human renin.15 Mouse plasma renin concentration (PRC) was measured as described previously.16 Briefly, aliquots of mouse plasma samples were incubated for 15 minutes at 37°C in the presence of binephrectomized rat plasma as a source of AGT. Produced Ang I concentrations were determined by radioimmunoassay.17
Statistics
The Mann–Whitney U test was used to compare control and genetically engineered animals. Data are represented as SEM. Statistical tests were considered significant if P
0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Expression of Human AGT mRNA in Various Tissues of Male and Female TG Mice
To investigate whether human AGT is directly implicated in vessel wall remodeling, we used a mouse line carrying human AGT as a transgene in addition to the endogenous mouse AGT. Plasma concentration of human AGT was higher in male (5393 nmol/L±1571 nmol/L) than in female mice (3716 nmol/L±682 nmol/L; Figure 2); these values correspond with concentrations that are 100- to 280-fold (for male) and 90- to 150-fold (for female) higher than in normal human plasma (20 to 30 nmol/L). The higher plasma human AGT value observed in male animals can be related to the marked AGT expression in male kidney when compared with female kidney (see below). To assess the absence of significant cleavage of human AGT by mouse renin, we measured mouse PRC, a highly sensitive indicator of angiotensin peptide levels, in Hu-AGT-TG mice and control mice. The comparison of mouse PRCs between male and female Hu-AGT-TG mice and their controls showed no difference between any of the groups (Figure 3).
|
|
The kidney of male Hu-AGT-TG mice is a major site of human AGT expression, because in situ hybridization revealed a high level of human AGT mRNA in the epithelial cells of the proximal convoluted tubules of male Hu-AGT-TG mice (Figure 4A and 4B). Only a low level of human AGT mRNA expression was detected in the proximal convoluted tubules of female Hu-AGT-TG mice (Figure 4C). As a control, no human AGT mRNA was detected in the kidneys of WT mice (Figure 4D). Human AGT mRNA was observed at low level in cardiomyocytes (Figure 4E and 4F) and was hardly detectable in the adipose tissue of both male and female transgenic mice (Figure 4G and 4H). Northern blot analysis showed a high level of human AGT mRNA in the male kidney and a very low level of transgene expression in the female kidney (data not shown). Human AGT mRNA was hardly detectable in the heart, brain, and adipose tissue of both sexes (data not shown).
|
Altogether, these results show that the human AGT transgene is expressed variably, according to tissues and gender. Among the tissues studied, human AGT is strikingly expressed in the male kidney and at much lower levels in all other tissues. For this reason, we compared renal artery wall thickness to other territories.
Arterial Wall Thickness in Various Tissues of Male and Female Transgenic Mice
The vascular wall thickness of arterioles in the kidney was measured in 20 to 25 vessels of every animals studied (six 60-day-old male Hu-AGT-TG mice and 11 age- and sex-matched control mice). Arteriole wall thickness was 21.5% lower in male Hu-AGT-TG mice than in male control mice (P=0.002; Figure 5A) in arteries of which the maximum external diameter was between 10 and 150 µm. Larger arteries (diameter between 250 and 600 µm) did not show this dystrophy. The measurement of vascular wall thickness of kidney arterioles in 20 vessels of five 15-day-old male Hu-AGT-TG mice and 4 age-and-sex-matched control mice showed a significant reduction in arterial wall thickness of 24.7% (P<0.001; Figure 5A). Measurement of the vessel wall thickness of kidney arterioles of 20 vessels in three 5-day-old male Hu-AGT-TG mice and 3 age- and sex-matched control mice showed no difference in arterial wall thickness. The vessel wall thickness of kidney arterioles was also measured in four 60-day-old female Hu-AGT-TG mice and in 4 age- and sex-matched control mice: no difference in arterial wall thickness was observed between female Hu-AGT-TG mice and control mice (Figure 5B). In other organs and vascular beds of male and female mice, adipose tissue and heart (Figure 5B), and mesenteric artery tree (data not shown), no difference in vessel wall thickness was observed between Hu-AGT-TG mice and their controls.
|
Density of VSMC in the Vessel Wall
To evaluate whether the reduction in vascular wall thickness of renal arterioles in male Hu-AGT-TG mice is because of hypotrophy or hypoplasia of the smooth muscle cell layer, we measured the density of VSMCs in kidney vessels of three 60-day-old WT and 3 age- and sex-matched Hu-AGT-TG mice. In each mouse, the density of VSMCs was evaluated in 4 vessels. No difference in VSMC density was obtained between WT and Hu-AGT-TG (data not shown). This means that the reduction in vascular wall thickness of kidney vessels in male Hu-AGT-TG mice is because of a lower number of cells and not because of cells of a smaller size in the smooth muscle cell layer.
Apoptosis and VSMC Proliferation
Our data indicate that a high expression of human AGT regulates negatively the growth of renal arterioles in male mice. This may be a consequence of increased apoptosis of VSMCs in the vascular wall or reduced proliferation of VSMCs. Alternatively, it might be because of a reduced recruitment of pericytes, which are the progenitor cells of the differentiated vascular wall cells. To distinguish between these possibilities, we measured apoptosis by using activated caspase-3 immunostaining and the TUNEL technique. No specific apoptosis signal was detected in kidney arteries or arterioles from 5-day-old male and female Hu-AGT-TG or 60-day-old male and female Hu-AGT-TG mice (results not shown). By using the proliferating cell nuclear antigen and Ki-67 immunostaining, a specific marker for cell proliferation, no difference in VSMC proliferation rate was observed between 5-day-old male and female Hu-AGT-TG mice (results not shown). A putative in vitro effect of human AGT on VSMC proliferation was evaluated by measuring 3H-thymidine incorporation in cultured HUSMCs and HAoSMCs. Concentrations of human AGT in the range of 1 to 200 nmol/L did not alter the proliferation rate of either cell line (Figure 6A and 6B). Even very high doses of human AGT (5000 nmol/L) did not alter the proliferation of HUSMCs, HAoSMCs or rat aortic smooth muscle cells (data not shown).
|
If the reduced growth of kidney small arterioles is not because of smaller cells (hypotrophy), a lower proliferation rate, or increased apoptosis, the cause for the differential growth between control and Hu-AGT-TG must not be intrinsic to the vascular wall of the small arterioles but rather a consequence of cell recruitment from the surrounding stroma, that is, pericyte recruitment. PDGF-B and its receptor (PDGF-Rß) play a major role in pericytes recruitment. We evaluated the level of PDGF-B mRNA and PDGF-Rß mRNA in male mice at day 5 and day 15 by in situ hybridization. The level of PDGF-B mRNA expression was low and did not vary between day 5 and 15 in Hu-AGT-TG and was similar to that of control mice (data not shown). In contrast, the level of PDGF-Rß mRNA is age- and genotype-specific (Figure 7). Using a scale of gradation from 1+ to 4+, the level of PDGF-Rß expression in small arterioles and also glomeruli was the highest at day 5 in Hu-AGT-TG males (mean value of 5 mice, 3.6), and then decreased from day 5 to day 15 (mean value of 6 mice, 2.7). A similar decrease occurred in control mice but starting at a lower level at day 5 (mean value of 3, 3.0) and reaching almost background noise level at day 15 (mean value of 5, 1.2). Therefore, during the first days of life, PDGF-Rß expression was more marked in renal arterioles in Hu-AGT-TG than in WT mice.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study shows that a high level of expression of human AGT is associated with a clear decrease of renal arteriole thickness, suggesting that AGT, per se, can influence vascular remodeling in rodents. Previous studies have shown that the lack of AGT in transgenic gene–deficient mice is accompanied by a marked increase in renal artery thickness.18–20 However, this observation could not be unambiguously attributed to a direct effect of AGT on the renal vasculature, because these mice have a marked decrease in blood pressure and an alteration in renal function, which may influence renal vascular remodeling. Indeed, similar renal arteriole dystrophies have been observed in mice in which other genes of the renin–angiotensin system have been inactivated.12,21–23
Our study was designed to evaluate the possible role of AGT, per se, on the vascular wall. For this purpose, we used a genetically engineered animal model in which an overexpression of AGT was not accompanied by a significant alteration in angiotensin production. The observed clear reduction in renal arteriole wall thickness cannot be attributed to gross hemodynamic pertubations, because Hu-AGT-TG mice have normal blood pressure. That human AGT is directly involved in this effect is supported by several arguments. First, in vitro, human AGT is cleaved at a very low rate by mouse renin at physiological pH; purified renin obtained from either human or mouse species is &500-fold less active on heterologous than on the homologous substrate.24,25 Second, in our study, human AGT was not cleaved at a detectable extent by mouse renin, because PRC of male and female Hu-AGT-TG mice was comparable with their controls; PRC is a highly sensitive marker of intrarenal angiopeptide levels as a slight increase in Ang II concentration downregulates renin production and circulating renin concentration (PRC) by negative feedback.26 Third, moreover, if high levels of Ang II were to be produced in Hu-AGT-TG mice, they would have been expected to have a reverse effect of what was observed, because Ang II exerts a well-documented growth-stimulatory effect on vessels.27 Finally, however, it may be that AGT, at this supraphysiological concentration, is cleaved by another and still unknown pathway leading to the generation of peptide, such as Ang (1-7), or/and angiotensin IV. Ang (1-7)– has been reported to attenuate neointimal formation after stent implantation in the rat.28
There is a relationship between the local level of human AGT expression and the vascular effect. There is a 21% reduction in renal arteriole thickness only in male Hu-AGT-TG mice where the transgene is markedly expressed, compared with females. The onset of difference in arteriole wall thickness between WT and Hu-AGT-TG mice occurs between day 5 and day 15. This period corresponds to the last wave of glomeruli and nephron differentiation. In female TG mice, where human AGT is expressed at a much lower level in the kidney, there is no appreciable AGT effect on renal artery thickness. In other organs where there is a low level of AGT expression in male and female Hu-AGT-TG mice (heart, adipose tissue, and mesenteric artery tree), there is no dystrophy in the vascular wall thickness. This is in favor of a relationship between AGT level expression and the degree of vascular reduction. However, a final conclusion cannot be drawn, because in other organs, in which a high level of human AGT transgene expression was detected, in the liver and in the adrenals, almost all of the vessels were -actin negative and their wall thickness could not be evaluated.
In the proximal convoluted tubules, human AGT mRNA was detected, and it could be hypothesized that AGT is released into the lumen of the tubules. However, our data are rather in favor of a local effect in the interstitium where blood vessels are located. The absence of the AGT effect in other vascular territories despite high circulating levels further suggests that AGT exerts a paracrine rather than an endocrine action on the kidney arterial walls of male Hu-AGT-TG mice.
Our data raise the question of the mechanism of action by which AGT modulates vascular wall remodeling. Remodeling involves VSMC growth and migration, as well as production of extracellular matrix.29 AGT affects endothelial cell proliferation,7 but an effect on VSMC proliferation or migration has not been reported. In our study, there was no evidence for proapoptotic effects of AGT in renal arterioles or in other vascular beds of newborn and adult Hu-AGT-TG mice. There was also no evidence for an in vitro antiproliferative effect of AGT on VSMCs.
Another possible mechanism to explain the difference in arteriole wall thickness between control and Hu-AGT-TG mice involves the fate of pericytes during embryogenesis. Pericytes are precursor cells of the differentiated vascular wall cells.30 During embryonic vascular wall remodeling, an excess of AGT may affect recruitment, proliferation, migration, or differentiation of pericytes into VSMCs. In the present study, we find that AGT does not operate through hyperplasia, thus supporting the hypothesis of a role for pericytes recruitment in the regulation of arteriole growth. Several factors are involved in vascular wall remodeling, among them the PDGF system31 for small vessels and the angiopoietin-1/tie-2 ligand receptor pair for large blood vessels.30 The observation of PDGF-Rß expression evaluated by in situ hybridization shows that, at the time of terminal kidney differentiation, PDGF-Rß progressively decreases to reach a minimal level at day 15 in control animals, whereas it remains high in Hu-AGT-TG mice at the same age. The persistence of a high level of expression of PDGF-Rß is somewhat paradoxical, because it occurs in animals with a high AGT circulating concentration, a condition responsible for the thinning of vascular wall thickness. Relatively high PDGF-Rß expression may be part of a counterregulation mechanism for the AGT effect on VSMCs. In any case, it may be proposed that the small arterioles in the kidney have a regulation process different from other arteries.
Perspectives
The data reported raise several questions. First, the mechanism of action of AGT on vascular remodeling; because of its effect on endothelial cells, AGT may interfere with the PDGF system and alter vessel maturation. Alternatively, AGT may interact with extracellular matrix proteins or cell surface proteins. Maspin, another member of the serpin family with antiangiogenic and antitumoral effects, interacts with extracellular matrix collagen I and III.32 Second, the physiological role, if any, of AGT in vessel wall remodeling because AGT effects were observed only in supraphysiological expression of human AGT in the kidney. High local levels of AGT may contribute to abnormal vascular remodeling, together with its action on neoangiogenesis. Such an effect accounts for the marked antiangiogenic and antitumoral effects of AGT in 2 experimental tumor models in mice, the human MDA mammary carcinoma and the murine B16-F10 melanoma.8
|
Acknowledgments |
|---|
We thank Marie-Thérèse Morin and Françoise Mongiat for excellent technical assistance, Ferdinand Le Noble for helpful discussions, Annie Michaud for the measurements of the PRCs, Hoffmann La Roche for recombinant human renin for the human AGT-radioimmunoassay, and Cecilia Bondjers for the gift of the cloned PDGF-B and PDGF-Rß cDNA. Dr Brand was supported by fellowships from the Deutsche Forschungsgemeinschaft (BR 2262/1-1) and the Collège de France.
|
Footnotes |
|---|
The first 2 authors contributed equally to this work.
Received March 18, 2005; first decision April 9, 2005; accepted March 27, 2006.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Tewksbury DA. Angiotensinogen: biochemistry and molecular biology. In: Laragh JH, Brenner BM, eds. Hypertension. New York, NY: Raven Press; 1990: 1197–1216.
2. Celerier J, Schmid G, Le Caer JP, Gimenez-Roqueplo AP, Bur D, Friedlein A, Langen H, Corvol P, Jeunemaitre X. Characterization of a human angiotensinogen cleaved in its reactive center loop by a proteolytic activity from Chinese hamster ovary cells. J Biol Chem. 2000; 275: 10648–10654.
3. Zhang M, Volpert O, Shi YH, Bouck N. Maspin is an angiogenesis inhibitor. Nat Med. 2000; 6: 196–199.[CrossRef][Medline] [Order article via Infotrieve]
4. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999; 285: 245–248.
5. Miao RQ, Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood. 2002; 100: 3245–3252.
6. O’Reilly MS, Pirie-Shepherd S, Lane WS, Folkman J. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science. 1999; 285: 1926–1928.
7. Celerier J, Cruz A, Lamande N, Gasc JM, Corvol P. Angiotensinogen and its cleaved derivatives inhibit angiogenesis. Hypertension. 2002; 39: 224–228.
8. Bouquet C, Lamandé N, Brand M, Gasc J-M, Jullienne B, Faure G, Griscelli F, Opolon P, Connault E, Perricaudet M, Corvol P. Suppression of angiogenesis, tumor growth and metastasis by adenovirus-mediated gene transfer of human angiotensinogen. Mol Ther. In press.
9. Campbell DJ, Habener JF. Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat. J Clin Invest. 1986; 78: 31–39.[Medline] [Order article via Infotrieve]
10. Naftilan AJ, Zuo WM, Inglefinger J, Ryan TJ Jr, Pratt RE, Dzau VJ. Localization and differential regulation of angiotensinogen mRNA expression in the vessel wall. J Clin Invest. 1991; 87: 1300–1311.[Medline] [Order article via Infotrieve]
11. Kakinuma Y, Hama H, Sugiyama F, Yagami K, Goto K, Murakami K, Fukamizu A. Impaired blood-brain barrier function in angiotensinogen-deficient mice. Nat Med. 1998; 4: 1078–1080.[CrossRef][Medline] [Order article via Infotrieve]
12. Yanai K, Saito T, Kakinuma Y, Kon Y, Hirota K, Taniguchi-Yanai K, Nishijo N, Shigematsu Y, Horiguchi H, Kasuya Y, Sugiyama F, Yagami K, Murakami K, Fukamizu A. Renin-dependent cardiovascular functions and renin-independent blood-brain barrier functions revealed by renin-deficient mice. J Biol Chem. 2000; 275: 5–8.
13. Yang G, Merrill DC, Thompson MW, Robillard JE, Sigmund CD. Functional expression of the human angiotensinogen gene in transgenic mice. J Biol Chem. 1994; 269: 32497–32502.
14. Sibony M, Commo F, Callard P, Gasc JM. Enhancement of mRNA in situ hybridization signal by microwave heating. Lab Invest. 1995; 73: 586–591.[Medline] [Order article via Infotrieve]
15. Clauser E, Bouhnik J, Jaramillo HN, Auzan C, Corvol P, Menard J. Angiotensinogen production and consumption in the adrenalectomized rat. Endocrinology. 1985; 116: 274–280.
16. Fuchs S, Germain S, Philippe J, Corvol P, Pinet F. Expression of renin in large arteries outside the kidney revealed by human renin promoter/LacZ transgenic mouse. Am J Pathol. 2002; 161: 717–725.
17. Menard J, Catt KJ. Measurement of renin activity, concentration and substrate in rat plasma by radioimmunoassay of angiotensin I. Endocrinology. 1972; 90: 422–430.
18. Tanimoto K, Sugiyama F, Goto Y, Ishida J, Takimoto E, Yagami K, Fukamizu A, Murakami K. Angiotensinogen-deficient mice with hypotension. J Biol Chem. 1994; 269: 31334–31337.
19. Kim HS, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, Jennette JC, Coffman TM, Maeda N, Smithies O. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci U S A. 1995; 92: 2735–2739.
20. Nagata M, Tanimoto K, Fukamizu A, Kon Y, Sugiyama F, Yagami K, Murakami K, Watanabe T. Nephrogenesis and renovascular development in angiotensinogen-deficient mice. Lab Invest. 1996; 75: 745–753.[Medline] [Order article via Infotrieve]
21. Krege JH, John SW, Langenbach LL, Hodgin JB, Hagaman JR, Bachman ES, Jennette JC, O’Brien DA, Smithies O. Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature. 1995; 375: 146–148.[CrossRef][Medline] [Order article via Infotrieve]
22. Tsuchida S, Matsusaka T, Chen X, Okubo S, Niimura F, Nishimura H, Fogo A, Utsunomiya H, Inagami T, Ichikawa I. Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J Clin Invest. 1998; 101: 755–760.[Medline] [Order article via Infotrieve]
23. Esther CR Jr, Howard TE, Marino EM, Goddard JM, Capecchi MR, Bernstein KE. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest. 1996; 74: 953–965.[Medline] [Order article via Infotrieve]
24. Hatae T, Takimoto E, Murakami K, Fukamizu A. Comparative studies on species-specific reactivity between renin and angiotensinogen. Mol Cell Biochem. 1994; 131: 43–47.[CrossRef][Medline] [Order article via Infotrieve]
25. Fukamizu A, Sugimura K, Takimoto E, Sugiyama F, Seo MS, Takahashi S, Hatae T, Kajiwara N, Yagami K, Murakami K. Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. J Biol Chem. 1993; 268: 11617–11621.
26. Mazzolai L, Nussberger J, Aubert JF, Brunner DB, Gabbiani G, Brunner HR, Pedrazzini T. Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension. 1998; 31: 1324–1330.
27. Stouffer GA, Owens GK. Angiotensin II-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-ß. Circ Res. 1992; 70: 820–828.
28. Langeveld B, van Gilst WH, Tio RA, Zijlstra F, Roks AJ. Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension. 2005; 45: 138–141.
29. Mulvany MJ. Small artery remodeling and significance in the development of hypertension. News Physiol Sci. 2002; 17: 105–109.
30. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003; 9: 685–693.[CrossRef][Medline] [Order article via Infotrieve]
31. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997; 277: 242–245.
32. Blacque OE, Worrall DM. Evidence for a direct interaction between the tumor suppressor serpin, maspin, and types I and III collagen. J Biol Chem. 2002; 277: 10783–10788.
This article has been cited by other articles:
 |
|
 |
|
  F. Vincent, P. Bonnin, M. Clemessy, J.-O. Contreres, N. Lamande, J.-M. Gasc, J. Vilar, P. Hainaud, G. Tobelem, P. Corvol, et al. Angiotensinogen Delays Angiogenesis and Tumor Growth of Hepatocarcinoma in Transgenic Mice Cancer Res., April 1, 2009; 69(7): 2853 - 2860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Baker, T. Rahman, D. Hall, P. J Avery, B. M Mayosi, J. M C Connell, M. Farrall, H. Watkins, and B. Keavney The C-532T polymorphism of the angiotensinogen gene is associated with pulse pressure: A possible explanation for heterogeneity in genetic association studies of AGT and hypertension Int. J. Epidemiol., December 1, 2007; 36(6): 1356 - 1362. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||